{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-047701","form_type":"8-K","ticker":"RANI","cik":"0001856725","company_name":"Rani Therapeutics Holdings, Inc.","filed_at":"2025-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.340811+00:00","generated_at":"2026-05-24T02:28:17.718381+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Rani Therapeutics reports FY2024 net loss of $56.6M; cash to Q3 2025; RT-114 preclinical data positive","bullets":["FY2024 net loss of $56.6M vs $67.9M in 2023; cash and marketable securities $27.6M, expected to fund operations into Q3 2025.","Preclinical data for RT-114 (GLP-1/GLP-2 dual agonist) shows 111% relative bioavailability vs subcutaneous, with bioequivalence and comparable weight loss.","Preclinical data for semaglutide oral via RaniPill HC (RT-116) shows bioavailability, PK, and weight loss comparable to subcutaneous.","Phase 1 study of RT-114 for obesity expected to initiate mid-2025; partnership with ProGen for co-development of RT-114.","Impairment loss of $3.7M on construction-in-progress equipment; R&D expenses down $12.9M YoY due to workforce reduction."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-047701","json":"https://secwatch.observer/filing/0000950170-25-047701.json","markdown":"https://secwatch.observer/filing/0000950170-25-047701.md","text":"https://secwatch.observer/filing/0000950170-25-047701.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1856725/000095017025047701/0000950170-25-047701-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1856725/000095017025047701/rani-20250331.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T02:28:17.718381+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}